Kurume, Japan

Hisataka Inoue

This inventor holds 5 USPTO granted patents. Top assignee: Hisamitsu Pharmaceutical Company, Inc.. Active years: 1990-1995.


% Patents Active = 100.0

Average Co-Inventor Count = 7.7

ph-index = 1

Forward Citations = 13(Granted Patents)


Location History:

  • Kurume, JP (1990 - 1995)
  • Tosu, JP (1995)

Company Filing History:


Years Active: 1990-1995

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Hisataka Inoue: Innovator in Pharmaceutical Chemistry

Introduction

Hisataka Inoue is a prominent inventor based in Kurume, Japan. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 5 patents. His work focuses on the development of novel chemical compounds that have potential applications in medicine.

Latest Patents

Among his latest patents, Inoue has developed a diphenylthiazole derivative and phenylalkanoic acid derivatives. These innovations include a novel phenylalkanoic acid derivative represented by a specific formula, where n is an integer of 1-2, X is a halogen atom, alkoxyl group, or nitro group, R is a hydrogen atom or alkyl group, and Z is a hydrogen atom or acyl group. These compounds are expected to have significant therapeutic potential.

Career Highlights

Inoue is currently associated with Hisamitsu Pharmaceutical Company, Inc., where he continues to advance his research and development efforts. His work has been instrumental in creating new pharmaceutical products that can improve patient outcomes.

Collaborations

Inoue has collaborated with notable colleagues such as Masaru Saita and Yoshiki Deguchi. These partnerships have fostered innovation and have contributed to the success of his projects.

Conclusion

Hisataka Inoue's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a key innovator in the field. His ongoing work promises to lead to further advancements in medical science.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…